Palvella Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Palvella Therapeutics, Inc. (PVLA) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$17.43 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2025-03-31
- Palvella Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$17.43M, a 548.87% decline from fiscal 2023.
- Palvella Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was $3.88M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|
| 2024-12-31 | -$17.43M 10-K · filed 2025-03-31 |
| 2023-12-31 | $3.88M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |